Skip to content

Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy

Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06737458
Enrollment
40
Registered
2024-12-17
Start date
2023-07-01
Completion date
2024-07-01
Last updated
2024-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bupivacaine, Dexmedetomidine, Erector Spinae Plane Block, Mastectomy, Pain Management, Serratus Anterior Plane Block, Ultrasound

Brief summary

This study aimed to compare the serratus plane block versus the erector spinae plane block with dexmedetomidine added to bupivacaine for acute pain management after breast surgeries.

Detailed description

Approximately 40-60% of breast surgery patients endure severe acute postoperative pain, with over 10% of patients experiencing severe pain for six to twelve months (post-mastectomy pain syndrome). Dexmedetomidine has analgesic properties, which could be related to the stimulation of α2 adrenoceptors, inhibition of nerve conduction through C and Aδ fibers, and the local release of encephalin. Serratus plane block (SPB) is an effective approach for breast surgery analgesia due to its simplicity of delivery, minimal risk of adverse effects, and ability to provide significant pain relief. The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB can be given unilaterally during modified radical mastectomy.

Interventions

Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women aged \>20 years. * Patient's approval. * American Society of Anesthesiologists (ASA) physical status I-II. * Patients underwent breast surgeries.

Exclusion criteria

* Known allergy to local anesthetics, opioids, or dexmedetomidine medications. * Advanced heart block, ventricular dysfunction. * Skin infection at the site of injection. * Pre-existing chronic pain. * Coagulopathies, significant liver or renal insufficiency.

Design outcomes

Primary

MeasureTime frameDescription
Total dose of pethidine consumption24 hours postoperativelyPatients get 1 g paracetamol IV like clockwork. Salvage absence of pain as bolus IV pethidine at 0.5 mg/kg was managed if NRS \> 3

Secondary

MeasureTime frameDescription
Intraoperative fentanyl consumptionIntraoperativelyIn case the cruel blood vessel weight (Outline) or heart rate (HR) went over 20% of pattern values, additional bolus dosages of 0.5 µg/kg IV fentanyl were given.
Heart rateEvery 15 minutes until the end of the surgery (Up to 2 hours)Heart rate was measured preoperatively and intraoperatively every 15 minutes until the end of the surgery.
Mean arterial pressureEvery 15 minutes until the end of the surgery (Up to 2 hours)Mean arterial pressure was measured preoperatively and intraoperatively every 15 minutes until the end of the surgery.
Degree of pain24 hours postoperativelyEach patient was instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents no pain while 10 represents the worst pain imaginable). NRS was assessed at post anesthesia care unit, 1, 2, 6, 12, 18, and 24 hours postoperatively
Incidence of complications24 hours postoperativelyIncidence of complications such as hypotension, bradycardia, and postoperative nausea and vomiting (PONV) were recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026